Can I Take Resveratrol with Repatha (Evolocumab)?

Why This Combination Raises Questions

Resveratrol supplements have gained popularity among patients already taking prescription lipid-lowering therapies. The concern typically centers on two properties: resveratrol's ability to inhibit cytochrome P450 enzymes in laboratory studies, and its weak estrogenic activity at higher doses. Patients prescribed Repatha (evolocumab) for familial hypercholesterolemia or established atherosclerotic cardiovascular disease (ASCVD) reasonably ask whether adding resveratrol could interfere with their injection.

How Evolocumab Is Cleared from the Body

Repatha is a fully human IgG2 monoclonal antibody. Unlike small-molecule statins or fibrates, monoclonal antibodies are not processed through hepatic cytochrome P450 pathways. They are degraded by intracellular proteolysis after receptor-mediated endocytosis [1]. This means the entire CYP enzyme system, whether induced or inhibited by a supplement, is irrelevant to evolocumab's clearance. The Repatha prescribing information confirms no clinically meaningful pharmacokinetic interactions with drugs metabolized by CYP enzymes [2].

Why CYP Inhibition Does Not Apply Here

A 2010 study in Drug Metabolism and Disposition demonstrated that resveratrol inhibits CYP3A4 and CYP1A2 activity in human liver microsomes, with IC50 values in the low micromolar range [3]. These findings prompted legitimate caution for patients on CYP3A4-substrate drugs like atorvastatin or simvastatin. But evolocumab never encounters these enzymes during its metabolism. The interaction pathway simply does not exist for this drug-supplement pair.

Pharmacokinetic Analysis: No Conflict at the Metabolic Level

The pharmacokinetic profiles of evolocumab and resveratrol operate through entirely separate systems. Evolocumab binds circulating PCSK9 protein, is internalized via target-mediated disposition, and is broken down into amino acids through lysosomal proteolysis [1]. Its elimination half-life ranges from 11 to 17 days at steady state.

Resveratrol's Metabolic Fate

Resveratrol, by contrast, undergoes rapid first-pass metabolism in the gut and liver. Oral bioavailability is extremely low, estimated at less than 1% for the parent compound in a pharmacokinetic study of healthy volunteers [4]. The dominant metabolites are resveratrol-3-O-sulfate and resveratrol-3-O-glucuronide, formed by sulfotransferases (SULTs) and UDP-glucuronosyltransferases (UGTs), not by CYP enzymes at physiologic doses [4]. Peak plasma concentrations of free resveratrol after a 500 mg oral dose reach approximately 50 to 100 ng/mL, levels far below those needed for meaningful CYP3A4 inhibition in intact human hepatocytes.

What the Clinical Data Show

No published case reports, pharmacovigilance signals, or clinical trials have documented an adverse interaction between any PCSK9 inhibitor and resveratrol. The FDA Adverse Event Reporting System (FAERS) database does not flag this combination. A 2019 systematic review in Nutrients covering resveratrol's drug interactions found no entries related to monoclonal antibody therapies [5].

Pharmacodynamic Considerations Worth Knowing

While the pharmacokinetic picture is clean, two pharmacodynamic properties of resveratrol deserve attention for patients on Repatha.

Antiplatelet Effects

Resveratrol inhibits platelet aggregation through COX-1 suppression and thromboxane A2 reduction. A randomized crossover trial (N=40) showed that 400 mg/day of trans-resveratrol significantly reduced collagen-stimulated platelet aggregation compared to placebo [6]. For most patients taking Repatha alone, this poses no problem. The concern arises when patients are simultaneously on anticoagulants (warfarin, apixaban) or dual antiplatelet therapy (aspirin plus clopidogrel), which is common in the post-ASCVD population that Repatha serves. The FOURIER trial enrolled patients with established vascular disease, and 93% were on antiplatelet therapy at baseline [7].

If you take Repatha alongside an anticoagulant or antiplatelet agent and want to add resveratrol, discuss bleeding risk with your prescriber. Signs to watch for include unusual bruising, prolonged bleeding from cuts, blood in stool, or dark urine.

Weak Estrogenic Activity

Resveratrol binds estrogen receptor beta (ERβ) with moderate affinity, acting as a phytoestrogen at doses above 500 mg/day [8]. This property has not been shown to alter LDL receptor expression or PCSK9 levels in human studies. A 2014 trial in Cell Metabolism found that 150 mg/day of resveratrol for 30 days did not change total cholesterol, LDL-C, or HDL-C in obese men [9]. The estrogenic activity is more relevant for patients with hormone-sensitive conditions (breast cancer history, endometriosis) than for the evolocumab interaction question specifically.

Do Resveratrol and Evolocumab Have Additive LDL-Lowering Effects?

This is a common patient question, and the honest answer is: probably not in any clinically meaningful way. Evolocumab reduces LDL-C by 59% on average when added to statin therapy, as demonstrated in the FOURIER trial (N=27,564), which also showed a 15% reduction in major adverse cardiovascular events over a median 2.2-year follow-up [7].

Resveratrol's Lipid Effects Are Small

A 2019 meta-analysis of 21 randomized controlled trials (N=1,302) in the journal Pharmacological Research found that resveratrol supplementation reduced LDL-C by a mean of 4.48 mg/dL (95% CI: −8.46 to −0.50) [10]. That effect is roughly 1/30th the magnitude of evolocumab's LDL reduction. Total cholesterol dropped by 5.69 mg/dL, and triglycerides decreased by 11.52 mg/dL [10].

Complementary But Not Synergistic

The mechanisms are different. Evolocumab blocks PCSK9 from binding to LDL receptors on hepatocytes, increasing receptor recycling and LDL clearance from the bloodstream [1]. Resveratrol may modestly upregulate SIRT1 and AMPK pathways that influence lipid metabolism, but these effects have been inconsistent across human trials [9]. There is no evidence of pharmacodynamic combination or interference between the two.

Patients who expect resveratrol to meaningfully augment their Repatha response should be counseled that the data do not support this expectation. The supplement is not a substitute for guideline-directed lipid therapy.

Dose-Separation and Practical Guidance

Because no pharmacokinetic interaction exists, no specific dose-separation window is required between resveratrol and evolocumab. Repatha is administered as a 140 mg subcutaneous injection every 2 weeks or 420 mg once monthly [2]. Resveratrol is taken orally, typically in doses of 100 to 500 mg daily. These routes do not compete for absorption.

What to Tell Your Prescriber

Before starting resveratrol (or any supplement), inform your prescribing clinician. Bring the product label so the specific dose and formulation are documented. Key points to discuss:

• Your current anticoagulant or antiplatelet regimen, given resveratrol's antiplatelet properties
• Any history of hormone-sensitive conditions, given resveratrol's ERβ activity
• Other supplements you take that also affect CYP3A4, such as St. John's wort or grapefruit extract, which could interact with co-prescribed statins even though they do not affect Repatha itself

Quality and Purity Concerns

Resveratrol supplements are not FDA-regulated for purity or potency. A 2015 analysis published in the Journal of Functional Foods tested 14 commercial resveratrol products and found that actual trans-resveratrol content ranged from 11% to 109% of label claims [11]. Patients on Repatha who choose to supplement should select products verified by third-party testing organizations (USP, NSF International, or ConsumerLab).

Monitoring Recommendations for Patients Taking Both

No additional laboratory monitoring is required solely because of this combination. Standard evolocumab monitoring applies.

Lipid Panel Schedule

The Endocrine Society and AHA/ACC guidelines recommend checking a fasting lipid panel 4 to 12 weeks after initiating or adjusting PCSK9 inhibitor therapy, then every 3 to 12 months depending on response [12]. This schedule is sufficient to detect any unexpected lipid changes when adding resveratrol.

Watch for Bleeding Signals

For patients on concurrent anticoagulation, monitor INR (if on warfarin) at the usual intervals. No dose adjustment to warfarin is typically needed for resveratrol at doses under 500 mg/day, but individual variation exists. Report any new or worsening bruising, epistaxis, or gingival bleeding.

Injection-Site Reactions

Evolocumab injection-site reactions (erythema, pain, bruising) occur in approximately 5.7% of patients per the Repatha label [2]. Resveratrol's antiplatelet activity could theoretically increase injection-site bruising. This has not been formally studied, but it is biologically plausible. If injection-site bruising worsens after starting resveratrol, bring this to your clinician's attention.

What to Do If You Are Already Taking Both

If you are already taking resveratrol with Repatha and have experienced no adverse effects, no changes are likely needed. Confirm the following with your care team at your next visit:

• Your LDL-C remains at goal (typically <70 mg/dL for established ASCVD, or <55 mg/dL under ESC/EAS 2019 guidelines) [13]
• No new bleeding symptoms have developed
• Your resveratrol dose does not exceed 500 mg/day, which is the upper boundary of most studied regimens
• Any co-prescribed statins are being monitored per their own interaction profiles, since resveratrol's CYP3A4 inhibition is relevant to atorvastatin, simvastatin, and lovastatin even though it is not relevant to evolocumab

Patients whose LDL-C is above target should not rely on adding resveratrol as a corrective strategy. Dose titration of evolocumab, statin intensification, or addition of ezetimibe are evidence-based next steps per the 2018 AHA/ACC Cholesterol Guideline [12].